Stockscreener 앱 받기
82.47
1.14%
-0.95
시간 외 거래:
86.67
4.20
+5.09%
전일 마감가:
$83.42
열려 있는:
$83.56
하루 거래량:
582.94K
Relative Volume:
1.08
시가총액:
$8.82B
수익:
$612.78M
순이익/손실:
$-86.37M
주가수익비율:
-51.22
EPS:
-1.61
순현금흐름:
$-62.91M
1주 성능:
-9.94%
1개월 성능:
+5.27%
6개월 성능:
+26.88%
1년 성능:
+44.20%
1일 변동 폭
$81.83
$83.61
1주일 범위
$81.83
$91.52
52주 변동 폭
$56.83
$93.45
Intra Cellular Therapies Inc Stock (ITCI) Company Profile
명칭
Intra Cellular Therapies Inc
전화
(646) 440-9333
주소
135 ROUTE 202/206, BEDMINSTER, NY
ITCI을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| ITCI | 82.47 | 8.82B | 612.78M | -86.37M | -62.91M | -1.61 |
| ZTS | 176.42 | 79.51B | 9.15B | 2.43B | 2.31B | 4.92 |
| TAK | 13.53 | 42.89B | 30.27B | 1.93B | 3.45B | 0.444 |
| HLN | 9.43 | 42.57B | 14.26B | 1.55B | 0 | 0.3327 |
| TEVA | 16.49 | 18.51B | 16.77B | -959.00M | 1.37B | -2.00 |
| VTRS | 13.00 | 15.37B | 15.24B | -646.50M | 1.88B | 1.53 |
Intra Cellular Therapies Inc Stock (ITCI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-09-06 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2024-01-03 | 개시 | Robert W. Baird | Outperform |
| 2023-12-11 | 개시 | TD Cowen | Outperform |
| 2023-04-20 | 개시 | Morgan Stanley | Overweight |
| 2022-08-22 | 다운그레이드 | Goldman | Buy → Neutral |
| 2022-07-07 | 개시 | Mizuho | Buy |
| 2022-06-14 | 개시 | UBS | Buy |
| 2022-04-22 | 개시 | Piper Sandler | Neutral |
| 2022-02-16 | 개시 | Goldman | Buy |
| 2021-09-23 | 개시 | Needham | Buy |
| 2020-12-15 | 개시 | BofA Securities | Buy |
| 2020-12-10 | 개시 | Goldman | Buy |
| 2020-02-20 | 개시 | Evercore ISI | Outperform |
| 2020-01-31 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2019-12-24 | 재확인 | Canaccord Genuity | Buy |
| 2019-08-12 | 개시 | Jefferies | Buy |
| 2018-02-26 | 개시 | JP Morgan | Overweight |
| 2018-02-08 | 개시 | RBC Capital Mkts | Outperform |
| 2017-12-15 | 개시 | Canaccord Genuity | Buy |
| 2017-11-08 | 업그레이드 | SunTrust | Hold → Buy |
| 2017-09-07 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2017-08-30 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2017-08-24 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
| 2017-08-23 | 업그레이드 | Leerink Partners | Mkt Perform → Outperform |
| 2017-05-02 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2017-05-02 | 다운그레이드 | Leerink Partners | Outperform → Mkt Perform |
| 2017-05-01 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2016-12-16 | 개시 | Cantor Fitzgerald | Overweight |
| 2016-09-29 | 재확인 | RBC Capital Mkts | Outperform |
| 2016-09-29 | 다운그레이드 | SunTrust | Buy → Neutral |
모두보기
Intra Cellular Therapies Inc 주식(ITCI)의 최신 뉴스
Entropy Technologies LP Acquires Shares of 7,116 Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Simplify Asset Management Inc. Increases Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Intra-cellular therapies president sells $3.69 million in stock - Investing.com
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Position Increased by Aigen Investment Management LP - MarketBeat
FMR LLC Reduces Stake in Intra-Cellular Therapies Inc - GuruFocus.com
Intra-Cellular Therapies (NASDAQ:ITCI) Hits New 12-Month HighTime to Buy? - MarketBeat
Lisanti Capital Growth LLC Sells 24,760 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Intra-Cellular bolsters Caplyta data with another Phase III win - MSN
Principal Financial Group Inc. Acquires 18,865 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
TimesSquare Capital Management LLC Grows Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
M&G Plc Invests $9.08 Million in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Acquired by Wealth Enhancement Advisory Services LLC - MarketBeat
Intra-Cellular Therapies Stock Hits All-Time High of $90.37 - Investing.com India
Intra-Cellular Therapies Stock Hits All-Time High of $90.37 By Investing.com - Investing.com UK
Intra-Cellular Therapies Announces Presentations at the 2024 Psych Congress and NEI Congress - The Manila Times
Lifespeak Inc (LSPK-T) QuotePress Release - The Globe and Mail
Revenues Tell The Story For Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) As Its Stock Soars 26% - Simply Wall St
Intra-Cellular Therapies Inc (ITCI) Trading 3.56% Higher on Nov 6 - GuruFocus.com
Positive Phase III results for Intra-Cellular’s Caplyta in schizophrenia - The Pharma Letter
Intra-Cellular Therapies Announces Positive Topline Results - GlobeNewswire
Intra-Cellular Therapies (NASDAQ:ITCI) Sets New 1-Year High Following Analyst Upgrade - MarketBeat
Intra-Cellular Therapies' Treatment Reduces Schizophrenia Relapse Risk 63% - Benzinga
Intra-Cellular Therapies' SWOT analysis: CAPLYTA drives stock potential amid market expansion - Investing.com India
Intra-Cellular's schizophrenia drug meets main goal in late-stage trial - Reuters
Intra-Cellular Therapies Announces Positive Topline Results in Phase 3 Trial Evaluating CAPLYTA for the Prevention of Relapse in Patients with Schizophrenia - The Manila Times
Harbor Capital Advisors Inc. Boosts Stock Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Demystifying Intra-Cellular Therapies: Insights From 15 Analyst Reviews - Benzinga
Intra-Cellular Therapies (NASDAQ:ITCI) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says - MarketBeat
Leerink Partnrs Issues Optimistic Forecast for ITCI Earnings - MarketBeat
Emerald Advisers LLC Acquires 48,705 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Net Present Value Model: Intra-Cellular Therapies Inc’s Lenrispodun phosphate - GlobalData
(ITCI) Technical Pivots with Risk Controls - Stock Traders Daily
Here's What Analysts Are Forecasting For Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) After Its Third-Quarter Results - Yahoo Finance
Intra-Cellular price target raised to $135 from $130 at Cantor Fitzgerald - MSN
FY2027 Earnings Estimate for ITCI Issued By Leerink Partnrs - MarketBeat
Intra-Cellular Therapies Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
abrdn plc Has $18.36 Million Holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Intra-Cellular Therapies (ITCI) Reports Q3 Loss, Tops Revenue Estimates - MSN
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Sees Large Decrease in Short Interest - MarketBeat
Intra-Cellular Therapies Stock Hits All-Time High at $85 By Investing.com - Investing.com Australia
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Q3 2024 Earnings Call Transcript - Insider Monkey
Intra-Cellular: Q3 Earnings Snapshot - The Pioneer
ITCI Q3 Loss Wider Than Expected, Revenues Top on Higher Caplyta Sales - MSN
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Receives $96.62 Average Target Price from Brokerages - MarketBeat
Intra-Cellular Therapies Stock Hits All-Time High at $85 - Investing.com India
Intra-Cellular Therapies Reports Strong Q3 Growth - TipRanks
Intra-Cellular stock target raised on Caplyta sales outlook By Investing.com - Investing.com Canada
Intra-Cellular jumps on Q3 beat as Caplyta outlook brightens - MSN
Intra-Cellular Therapies Q3 2024 Earnings Preview - MSN
Intra-Cellular stock jumps on Caplyta outlook (ITCI:NASDAQ) - Seeking Alpha
Intra-Cellular Therapies (NASDAQ:ITCI) Sets New 1-Year HighStill a Buy? - MarketBeat
Intra Cellular Therapies Inc (ITCI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Intra Cellular Therapies Inc 주식 (ITCI) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Halstead Michael | President |
Nov 12 '24 |
Option Exercise |
23.94 |
22,869 |
547,484 |
22,869 |
| Halstead Michael | President |
Nov 12 '24 |
Sale |
89.12 |
22,869 |
2,038,079 |
0 |
| Halstead Michael | President |
Nov 13 '24 |
Sale |
88.38 |
18,714 |
1,654,021 |
0 |
0.54%
0.15%
자본화:
|
볼륨(24시간):